Comparative Pharmacology
Head-to-head clinical analysis: DARVOCET N 50 versus ORAMORPH SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVOCET N 50 versus ORAMORPH SR.
DARVOCET-N 50 vs ORAMORPH SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a weak mu-opioid receptor agonist; it also binds to sigma receptors. Acetaminophen inhibits prostaglandin synthesis via COX-1 and COX-2, thereby reducing pain and fever.
Morphine is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. Binding to mu-opioid receptors in the central nervous system (CNS) and peripheral tissues results in analgesia, euphoria, sedation, respiratory depression, and physical dependence. Morphine also activates descending inhibitory pathways and inhibits ascending nociceptive transmission.
1 tablet (propoxyphene 50 mg, acetaminophen 300 mg) orally every 4 hours as needed for pain, not to exceed 6 tablets per day.
10-30 mg orally every 8-12 hours, sustained-release; titrate as needed for pain.
None Documented
None Documented
Acetaminophen: 1.5-3 hours (therapeutic); 4-6 hours in overdose due to saturation of metabolism. Propoxyphene: 6-12 hours (parent); norpropoxyphene: 30-36 hours (active metabolite, accumulates with repeated dosing).
2–4 hours in adults; in controlled-release formulation, effective half-life is prolonged due to sustained absorption. Clinically, steady-state is achieved in 1–2 days.
Acetaminophen: renal (90-100% as metabolites within 24h; 2-4% unchanged). Propoxyphene: renal (25-30% unchanged; metabolites) and biliary/fecal (significant enterohepatic circulation).
Renal (approximately 90% as morphine-3-glucuronide and morphine-6-glucuronide, minor amounts of unchanged morphine, and other conjugates); biliary/fecal (approximately 10%).
Category C
Category C
Opioid Analgesic
Opioid Analgesic